SEOVF (Sernova Biotherapeutics) Debt-to-Equity : -0.03 (As of Jan. 2025)

View and export this data going back to 1998. Start your Free Trial

What is Sernova Biotherapeutics Debt-to-Equity?

Sernova Biotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2025 was $0.07 Mil. Sernova Biotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2025 was $0.31 Mil. Sernova Biotherapeutics's Total Stockholders Equity for the quarter that ended in Jan. 2025 was $-12.46 Mil. Sernova Biotherapeutics's debt to equity for the quarter that ended in Jan. 2025 was -0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sernova Biotherapeutics's Debt-to-Equity or its related term are showing as below:

SEOVF' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.11 Med: 0.01 Max: 0.17
Current: -0.03

During the past 13 years, the highest Debt-to-Equity Ratio of Sernova Biotherapeutics was 0.17. The lowest was -0.11. And the median was 0.01.

SEOVF's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs SEOVF: -0.03

Sernova Biotherapeutics Debt-to-Equity Historical Data

The historical data trend for Sernova Biotherapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Biotherapeutics Debt-to-Equity Chart

Sernova Biotherapeutics Annual Data

Trend

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

Debt-to-Equity

Get a 7-Day Free Trial

0.17

0.01

-0.04

Sernova Biotherapeutics Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Debt-to-Equity	Get a 7-Day Free Trial															0.17	-0.11	-0.05	-0.04	-0.03

Competitive Comparison of Sernova Biotherapeutics's Debt-to-Equity

For the Biotechnology subindustry, Sernova Biotherapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sernova Biotherapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sernova Biotherapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sernova Biotherapeutics's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Sernova Biotherapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sernova Biotherapeutics's Debt to Equity Ratio for the fiscal year that ended in Oct. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.073	+	0.34)	/	-9.418
	=	-0.04

Sernova Biotherapeutics's Debt to Equity Ratio for the quarter that ended in Jan. 2025 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.074	+	0.306)	/	-12.46
	=	-0.03

Sernova Biotherapeutics (OTCPK:SEOVF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sernova Biotherapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sernova Biotherapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sernova Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Biotherapeutics Inc (OTCPK:SEOVF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PSH0:Germany PSH0:Germany PSH0:Germany SVA:Canada

Address

700 Collip Circle, Suite 114, London, ON, CAN, N6G 4X8

Website

https://www.sernova.com

Sernova Biotherapeutics Inc is a clinical-stage company developing regenerative medicines. The company develops Cell Pouch with human donor cells or stem cells to create a biohybrid organ. The Cell Pouch is a implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones, or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.